5 Key Takeaways

• 1

  Aspirin's effect on cancer prevention varies by patient characteristics, with benefits seen in nonsmokers and those with lower BMI or family history of cancer.

• 2

  The analysis included 9,350 patients aged 70 and older, with a median follow-up of 4.5 years, showing no overall significant difference in cancer incidence.

• 3

  CHIP emerged as the strongest predictor of aspirin benefit, with 6% of patients carrying CHIP at or above the defined threshold.

• 4

  Current smoking was identified as the most important predictor for a detrimental effect of aspirin on cancer incidence.

• 5

  The study's limitations include a largely White population and uncertainty about the applicability of results to younger patients.